Fundraising FoxDomain Associates
Venture capitalPrinceton · Seed–Growth · 12 people tracked
Also known as DOMAIN ASSOCIATES, LLC
Find your way into Domain Associates
Each arrow is one introduction. Sign up to fill in the first one.
Ask John Prufeta to introduce you to Kim Kamdar
You →John · together at Medical Excellence Capital →Kim
Ask Jamie Chen to introduce you to Nicole Vitullo
You →Jamie · together at Antios Therapeutics →Nicole
Ask Sam Okafor to introduce you to Jesse Treu
You →Sam · together at Aldeyra Therapeutics →Jesse
- Brian Halak204 people can intro you
- Brian Dovey193 people can intro you
- James Blair12 people can intro you
Sign up to find every way you can get introduced to Domain Associates
- Your email: who you already know at Domain Associates, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Domain Associates team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
Domain Associates focuses on the biotech sector, having pioneered the first venture capital fund dedicated to biotech and managing multiple subsequent biotech-focused venture funds.
Source: firm website, verified Sep 29, 2026.
Team · 12 people
from the firm's website & curated & public directories
Founder mafia
2 people who came through Domain Associates went on to found or lead other companies.
What they invest in
from 45 of 59 portfolio companiesBiotech ×34Healthtech ×28Medical Devices ×15Digital Health ×6Deep Tech ×3Hardware ×3AI & Machine Learning ×2Wellness & Fitness ×2
HQs:United States×42
Investments · 59 tracked
founders shown can be your intro pathBy year:2026 · 12024 · 12021 · 12020 · 52017 · 12016 · 32015 · 72014 · 52012 · 42011 · 12010 · 52008 · 246 dated
Aldeyra Therapeutics is a biopharmaceutical company developing therapies for eye diseases and other conditions.
BiotechHealthtechMedical DevicesLexington, US
Todd C. Brady(Executive Officer, Director)inStephen Tulipano(Executive Officer)inScott L. Young(Executive Officer)inDr. Brady(President and Chief Executive Officer)
BoardJesse I. Treu(Director)inBen Bronstein(Director)
Board seatJesse Treu· per SEC Form D
Bionano develops optical genome mapping (OGM) systems and analysis software that detect structural variants and chromosomal aberrations across the genome.
BiotechHealthtechMedical DevicesSan Diego, US
Han Cao(Executive Officer)Gulsen Kama(Executive Officer)Mark Oldakowski(Executive Officer)inJonathan Dixon(Executive Officer)inR. Erik Holmlin(Executive Officer, Director)Alka Chaubey(Executive Officer)in
Board seatBrian Halak· per SEC Form D · $68.4M raise · filed Jan 2015
Co-investorsHudson Bay
Evofem Biosciences is a biopharmaceutical company that commercializes products for women's sexual and reproductive health, including PHEXX, a non-hormonal prescription vaginal contraceptive gel applied before intercourse, and SOLOSEC, an oral antimicrobial agent for treating bacterial vaginosis and trichomoniasis.
BiotechSan Diego, US
Ivy Zhang(Executive Officer)inSaundra Pelletier(Executive Officer, Director)inKelly Culwell(Executive Officer)inJustin J. File(Executive Officer)inAlexander A. Fitzpatrick(Executive Officer)Russell Barrans(Executive Officer)
Board seatKim Kamdar· per SEC Form D · $25M raise · filed May 2020
Co-investorsAdjuvant CapitalInvescoWoodford Investment Management
Align Technology is a medical device company that makes clear aligners (the Invisalign System) and intraoral scanners for orthodontic and restorative dental treatment.
HardwareHealthtechMedical DevicesMorrisville, US
Kelsey Wirth(Founder)Zia Chishti(Founder)
Co-investorsKleiner PerkinsQuestMark Partners
Atara Biotherapeutics develops allogeneic T-cell immunotherapies using its proprietary EBV T-cell platform to harness the immune system for treating disease.
BiotechHealthtechMedical DevicesThousand Oaks, US
AnhCo Nguyen(President and Chief Executive Officer)Isaac Ciechanover(Founder)
Co-investorsDag VenturesEcoR1 CapitalHEALTHCARE ROYALTY PARTNERSKleiner PerkinsFidelity Investments
aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.
BiotechHealthtechMedical DevicesSan Diego, US
Paul Schimmel(Founder)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)inFrederic Chereau(Executive Officer)
BoardAmir Nashat(Non-Management Director)inAkkaraju Srinivas(Non-Management Director)
Co-investorsCardinal PartnersEcoR1 CapitalSofinnova VenturesViking GlobalDomain PartnersPolaris Partners+2 more
Fractyl develops therapies for obesity and type 2 diabetes, focusing on non-drug-based approaches rooted in understanding metabolic disease mechanisms.
BiotechHealthtechMedical DevicesLexington, US
Jay Caplan(Founder)inHarith Rajagopalan(Founder)inLISA DAVIDSON(Executive Officer)inDiane Marcou(Executive Officer)in
BoardAllan Will(Director)inNimesh Shah(Director)in
Co-investorsBessemer Venture PartnersCatalio Capital Management, LPEmergent Medical Partners, LLPGeneral CatalystMithril Capital ManagementPolaris Partners+1 more
.png)
Geron is a biopharmaceutical company focused on developing therapies for blood cancer.
BiotechHealthtechLongevityMedical Devices
Michael D. West(Founder)Harout Semerjian(President and Chief Executive Officer)inMichelle J. Robertson(Executive Vice President, Chief Financial Officer, Treasurer and Interim Secretary)inJoseph Eid(Executive Vice President, Research and Development, Chief Medical Officer)inAhmed ElNawawi(Executive Vice President, Chief Commercial Officer)in
Co-investorsBioBritNew Enterprise Associates (NEA)Venrock
Sera Prognostics develops women's health diagnostics focused on pregnancy, including the PreTRM blood test that predicts an individual's risk of spontaneous preterm birth in singleton pregnancies and the LikeMine platform that compares pregnancy outcomes using U.S. pregnancy data.
BiotechDigital HealthFemTechHealthtechSalt Lake City, US
Douglas Fisher(Executive Officer)Jay Moyes(Executive Officer)inGregory C. Critchfield(Executive Officer, Director)inAndrew A. Sauter(Executive Officer)inZhenya Lindgardt(President and Chief Executive Officer)in
BoardMansoor Mirza(Director)
Co-investorsaMoonExcelestar VenturesIntermountain HealthOUP (Osage University Partners)UpStart VenturesVivo Capital+1 more
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.
BiotechWaltham, US
John Pallies(Executive Officer)inArlene Morris(Executive Officer, Director)inMichael A. Metzger(Chief Executive Officer)inKeith A. Goldan(Chief Financial Officer)in
BoardDennis Podlesak(Director)inIvor Royston(Director)
Co-investorsAisling CapitalATEM Capital FundAvoro Capital AdvisorsBioBritDelos CapitalEcoR1 Capital+6 more
Tandem Diabetes manufactures infusion sets—tubing systems with subcutaneous delivery sites—designed for use with insulin pumps to manage diabetes.
Digital HealthHardwareHealthtechMedical Devices
Kim BlickenstaffinJohn Sheridan(President, Chief Executive Officer)inRick Carpenter(Executive Vice President and Chief Technology Officer)inElizabeth Gasser(Executive Vice President and Chief Strategy and Product Officer)inShannon Hansen(Executive Vice President, Chief Legal, Privacy & Compliance Officer and Secretary)inJean-Claude Kyrillos(Executive Vice President, Chief Operating Officer)
Co-investorsHLM Investment Partners
Veracyte develops genomic diagnostic tests for cancer, offering laboratory developed tests for thyroid, prostate, bladder, and breast cancers performed in its CLIA-certified, high-complexity labs.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Bonnie H. Anderson(Executive Officer, Director)inJulie Brooks(Executive Officer)inShelly D. Guyer(Executive Officer)inMarc Stapley(Chief Executive Officer)in
BoardSamuel D. Colella(Director)Fred E. Cohen(Director)
Co-investorsCatalyst Health VenturesKleiner PerkinsJohnson & Johnson Innovation – JJDC
Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.
BiotechDeep TechDigital HealthMedical DevicesSan Diego, US
Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inANDRÉS BRATT-LEAL, Ph.D.(Co-Founder; Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)inDAMIEN MCDEVITT, Ph.D.(President and Chief Executive Officer)
Co-investorsARCH Venture PartnersLifeforce CapitalOrbiMedEDB InvestmentsSection 32Frazier Life Sciences+9 more
Truvian builds an on-site blood diagnostics platform that combines clinical chemistry, immunoassay, and hematology testing in a single compact instrument.
BiotechDigital HealthMedical DevicesSan Diego, US
Dena Marrinucci(Co-Founder & Chief Operating Officer)inMichael J. Mina(Chief Medical and Strategy Officer)in
Co-investorsDns CapitalGreatPoint VenturesWittington VenturesEmbark VenturesMedical Excellence CapitalXB Ventures+1 more
BiotechSan Mateo, US
Anthony Ford(Executive Officer)inMichael Kitt(Executive Officer)inKathleen Sereda Glaub(Executive Officer, Director)in
BoardKevin Starr(Director)inArthur Pappas(Director)Liam Ratcliffe(Director)
Board seatJesse Treu· per SEC Form D
Co-investorsPappas CapitalFidelity InvestmentsJennison AssociatesThird Rock Ventures
Currax Pharmaceuticals develops and markets a portfolio of therapies for chronic progressive diseases.
BiotechHealthtechLa Jolla, US
Preston Klassen(Executive Officer)inJoseph Hagan(Executive Officer)Michael Narachi(Executive Officer, Director)Thomas Cannell(Executive Officer)
BoardBrian H. Dovey(Director)in
Board seatBrian DoveyEckard Weber· per SEC Form D · $90M raise · filed Sep 2015
Co-investorsCross Creek AdvisorsMontreux Equity PartnersNew Enterprise Associates (NEA)Sofinnova VenturesDomain Partners
HealthtechDuluth, US
Anthony V. Lando(Executive Officer, Director)inTodd Meyer(Executive Officer)inDilip Paithanker(Executive Officer)Robert Leslie(Executive Officer)Dilip Paithankar(Executive Officer)in
BoardRebecca B. Robertson(Director)
Board seatJesse Treu· per SEC Form D
Co-investorsAccuitive Medical VenturesVersant Ventures
SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.
BiotechDeep TechDigital HealthHealthtechSouth San Francisco, US
Kenneth Greenberg(Co-Founder, President & CEO)in
Board seatBrian Halak· per SEC Form D · $125.5M raise · filed Jun 2026
Co-investorsVida VenturesLeaps by BayerARCH Venture PartnersFoothill VenturesIllumina VenturesMedical Excellence Capital+8 more
Achillion conducts research and development focused on addressing rare disease challenges through investigation of new therapeutic targets, modalities, and technologies.
BiotechHealthtech
Co-investorsConnecticut InnovationsPappas CapitalSV Health Investors
BiotechSan Francisco, US
Donald Manning(Executive Officer)Scott Harris(Executive Officer)Julien Mamet(Executive Officer, Director)Rick Orr(Executive Officer, Director)
BoardDennis Podlesak(Director)inEckard Weber(Director)
Co-investorsRed Tree Venture
Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.
BiotechHealthtechMendham, US
Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)inTamra Adams(Executive Officer)inAbel De La Rosa(Director)
BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)
Co-investorsAisling CapitalAltium CapitalAvego BioScience CapitalLifeSci Venture PartnersPontifax Venture CapitalAmzak Health+8 more
bioMérieux develops in vitro diagnostic systems and molecular testing panels for pathogen detection in clinical, food safety, and pharmaceutical quality control settings.
BiotechHealthtechMedical DevicesSan Diego, US
Todd Myers(Executive Officer)inChristopher Hibberd(Executive Officer, Director)Kenneth Buechler(Director)Paul McPherson(Executive Officer, Director)
BoardJames Blair(Director)James Scopa(Director)
Co-investorsKaiser Permanente VenturesMoore Venture Partners
Biopharmaceutical developer of tumor-selective PARP inhibitor cancer therapies, acquired by Sanofi-aventis in 2009.
Co-investorsAisling CapitalAsset Management CompanyCanaan PartnersKleiner PerkinsSPRINGROCK VENTURESVantagePoint Capital Partners
ChromaCode develops a High-Definition PCR (HDPCR) multiplexing platform that enables genomic solutions for oncology and precision medicine, offering faster results and cost-effective workflows through automated interpretation and cloud-based software.
AI & Machine LearningBiotechHealthtechMedical DevicesCarlsbad, US
Paul Flook(Executive Officer, Director)inGregory J. Gosch(Executive Officer, Director)Lynne Rollins(Executive Officer)Aditya Rajagopal(Director)inAxel Scherer(Director)
BoardJustin Klein(Director)in
Co-investorsAdjuvant CapitalGlobal BrainMoore Venture PartnersNew Enterprise Associates (NEA)Windham Capital PartnersDomain Partners+2 more
Colorescience is a professional skincare brand that develops mineral-based sun protection (SPF), skincare, and color correction products, originally created for post-procedure skin and marketed for all ages and skin types.
ConsumerDirect to ConsumerHealthtechWellness & FitnessCarlsbad, US
Stephen Loomis(Executive Officer)Mary Fisher(Executive Officer, Director)inTheodore Ebel(Executive Officer)Josie Juncal-Schwarz(Executive Officer)
BoardM Bolyard(Director)Brian Dovey(Director)in
Co-investors1315 CapitalAisling CapitalRevelation PartnersHealthCare Ventures, LLCLongwood FundMontreux Equity Partners+2 more
GenVault operates a GxP-compliant biorepository providing secure, temperature-controlled storage, sample management, and lab relocation services for biological, clinical, and biopharmaceutical materials.
BiotechHealthtechLogistics & Supply Chain
Co-investorsCross Creek AdvisorsQuestMark PartnersGreenspring AssociatesIn-Q-Tel
Locus Biosciences develops engineered bacteriophage therapies for treating bacterial infections and conditions in immunology, oncology, and CNS disorders.
AI & Machine LearningBiotechDeep TechHealthtechRaleigh, US
Paul Garofolo(CEO & Co-founder)NICK TAYLOR(Executive Officer)inNick Conley(Vice President of Technology (Co-founder of EpiBiome, acquired by Locus))in
BoardGEOFFREY GLASS(Director)inDAVID JOHNSTON(Director)BARY BAILEY(Director)
Co-investorsArtis VenturesAbstract VenturesHemisphere Ventures LLCLongitude CapitalStarlight VenturesTencent Holdings
BiotechRadnor, US
Scott Braunstein, MD(Executive Officer, Director)Edward F. Smith(Executive Officer)Joe Hulihan, MD(Executive Officer)
BoardNicole Vitullo(Director)Enrique J. Carrazana, MD(Director)Michael R. Dougherty(Director)
Co-investorsAvoro Capital AdvisorsBain Capital Life SciencesCanaan PartnersConnecticut InnovationsSofinnova VenturesFlare Capital Partners+1 more
San Diego DNA sequencing company behind the Sequencing by Binding short-read platform; acquired by Pacific Biosciences in 2021.
BiotechSan Diego, US
David S. Mullarkey(Executive Officer, Director)Arnold Oliphant(Executive Officer)inKen Song, M.D., Ph.D.(Executive Officer, Director)Kelly Perez(Executive Officer)John Murphy, Ph.D.(Executive Officer)Millard Y Chan(Chief Operating Officer, Secretary and Director)
Co-investorsARCH Venture PartnersATEL VenturesDCVC (Data Collective)Decheng CapitalLam CapitalPivotal Life Sciences+3 more
OraPharma develops pharmaceutical products and tools for dental professionals to address oral health concerns, serving dental practices and patients.
HealthtechMedical DevicesBridgewater, US
Co-investorsA-Rod CorpCanaan PartnersFrazier Life SciencesHealthCapOak Investment Partners
HealthtechHorsham, US
Eric Heil(Executive Officer, Director)
BoardDennis Podlesak(Director)Jesse Treu(Director)Richard Perlman(Director)Brian Murphy(Director)Peter Bach(Director)
Signifier Medical Technologies is a medical device company developing non-invasive treatments for snoring and mild sleep apnea.
Digital HealthMedical DevicesWellness & Fitness
Akhil Tripathi(Co-founder)Phil Radford(Chairman)John Saville Bentley(Chief Executive Officer)Thomas McCarthy(Chief Financial Officer)
Thermo Fisher provides life science products and laboratory equipment, including antibodies, consumables, biobanking resources, and Cryo-EM imaging systems for research labs and scientists.
BiotechEnterprise SoftwareHardwareHealthtechWaltham, US
Anthony Uzzo(Executive Officer, Director)inJoshua Geballe(Executive Officer, Director)James Gregory(Executive Officer, Director)Marc N. Casper(Executive Officer, Director)inAndrew J. Thomson(Executive Officer)Peter M. Wilver(Executive Officer)
Co-investorsARCH Venture PartnersBayMed Venture PartnersCross Creek AdvisorsEric F. ThiessenExcel Venture ManagementHeran Partners+7 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
CoLucid PharmaceuticalsKona MedicalTragara PharmaceuticalsAxial BiotherapeuticsBenvenue MedicalCelator PharmaceuticalsCoDa TherapeuticsCortheraEsperionExalys TherapeuticsExelixisGene SciencesKalidex PharmaceuticalsMilestone Pharmaceuticals, Inc.Miramar LabsOcunexus TherapeuticsOtonomyRegado BiosciencesRevision OpticsSequent MedicalSomaxon PharmaceuticalsVentiRx PharmaceuticalsVerteroXagenicZyga Technology
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 16
12 IPOs · 4 acquisitions · showing 13Aldeyra TherapeuticsNASDAQ: ALDXBionano GenomicsNASDAQ: BNGOEvofem BiosciencesOTC: EVFMAlign TechnologyNASDAQ: ALGNAtara BiotherapeuticsNASDAQ: ATRAaTYR PHARMANASDAQ: ATYRFractylNASDAQ: GUTSGeronNASDAQ: GERNSera PrognosticsNASDAQ: SERASyndax PharmaceuticalsNASDAQ: SNDXTandem Diabetes Care, Inc.NASDAQ: TNDMVeracyteNASDAQ: VCYTGenVaultacq. by Thermo Fisher Scientific
Portfolio news
latest coverage across their companiesSonoThera · finsmes.com · Jun 10, 2026
Aspen Neuroscience · prnewswire.com · Nov 20, 2025
Fund performance · per public LP disclosures
as of Mar 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Domain Excelsior Fund, LPLPs: Empire State Development – New York Ventures | 2022 | — | — | 12.49x | 0.00x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
IPO stake values · per SEC filings · 5
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Atara Biotherapeutics | 7.0% | $52.00 | Jul 2015 | $101.8M |
| Fractyl | 8.4% | $15.00 | Feb 2024 | $60M |
| Sera Prognostics | 8.4% | $16.00 | Jul 2021 | $41.2M |
| Syndax Pharmaceuticals | 14.6% | $12.00 | Mar 2016 | $30.5M |
| Aldeyra Therapeutics | 20.8% | $7.50 | May 2015 | $14.9M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Domain Associates made?
- Domain Associates has 59 tracked investments, 16 of which have exited, including 1 dated in the last 24 months.
- What stage does Domain Associates invest at?
- Domain Associates invests at the Seed, Series A, Series B, Series C, Growth stages.
- What is Domain Associates's typical check size?
- Domain Associates typically writes checks of $200K – $15M.
- What sectors does Domain Associates focus on?
- Domain Associates focuses on Biotech.
- Where is Domain Associates located?
- Domain Associates is headquartered in Princeton, US.
Co-investors · 35
Aisling Capital is an investment firm focused on companies developing and commercializing innovative healthcare products, services, and technologies.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
Versant Ventures operates in-house Discovery Engines staffed by multidisciplinary scientists in dedicated laboratory facilities to help launch new biotechnology companies alongside academic founders.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Johnson & Johnson Innovation is the innovation arm of Johnson & Johnson, working to advance life science innovation through early partnerships, incubation via JLABS, venture investing through JJDC, and late-stage partnerships to address global health challenges.
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.
Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'
Venrock is a venture capital firm investing across technology and healthcare, backing companies in fintech, developer infrastructure, life sciences, therapeutics, semiconductors, and consumer products.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
▶23 more co-investors
Pivotal Life SciencesFrazier Healthcare PartnersSeventure PartnersRiverVest Venture PartnersVensana CapitalPontifax Venture CapitalAvedro, Inc.Unknown VenturesMeritech Capital PartnersWildcat Venture PartnersForbionDeerfield Management CompanyAbingworthStanford UniversityNew Leaf Venture PartnersAlta PartnersAmplitude Venture CapitalOkapi Venture CapitalJDRF T1D FundSante VenturesCincyTechRTW Investments L.P.BioInnovation Capital
Firms observed investing alongside Domain Associates, from public investor directories. Shared companies are the overlap with Domain Associates's recorded portfolio.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
EQT Life Sciences (formerly LSP) is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally.
Neotribe Ventures is a venture capital firm that backs early and growth-stage entrepreneurs pursuing bold, category-defining ideas aimed at solving complex, high-impact problems.
Norwest is a venture capital and growth equity investment firm that has backed over 700 companies across technology, consumer, and healthcare over its 65-year history.